Jubilant Ingrevia Ltd

Jubilant Ingrev. Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Jubilant Ingrevia Ltd

₹ 690 -1.08%
31 Oct - close price
jubilantingrevia.com BSE: 543271 NSE: JUBLINGREA
About

Jubilant Ingrevia, a global integrated Life Science products and Innovative Solutions provider serving, Pharmaceutical, Nutrition, Agrochemical, Consumer and Industrial customers with our customised products and solutions that are innovative, cost-effective and conforming to excellent quality standards.

Jubilant Ingrevia’s portfolio also extends to custom research and manufacturing for pharmaceutical and agrochemical customers on an exclusive basis. [1]

Key Points

Leadership[1]
# 40+ years of legacy in Chemicals space, started in 1978
# Global player in Pyridine + Beta, Vitamin B3 and Acetic Anhydride.
# Serves 15 of the top 20 Global Pharma & 7 of the top 10 Global Agrochemical companies.
# Leading Low-Cost provider.

Website BSE NSE
  • Market Cap ₹ 10,990 Cr.
  • Current Price ₹ 690
  • High / Low ₹ 885 / 535
  • Stock P/E 38.2
  • Book Value ₹ 184
  • Dividend Yield 0.72 %
  • ROCE 11.2 %
  • ROE 8.88 %
  • Face Value ₹ 1.00
Edit ratios

Pros

  • Company has been maintaining a healthy dividend payout of 33.5%

Cons

  • Stock is trading at 3.75 times its book value
  • Company has a low return on equity of 9.24% over last 3 years.
  • Company might be capitalizing the interest cost
  • Promoter holding has decreased over last 3 years: -6.25%

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Commodities Chemicals Chemicals & Petrochemicals Specialty Chemicals

Part of BSE 500 Nifty 500 BSE SmallCap BSE Allcap BSE Commodities

Edit Columns
Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025
1,304 1,158 1,145 1,075 1,020 966 1,074 1,024 1,045 1,057 1,051 1,038 1,121
1,151 1,007 1,043 958 902 871 983 915 921 918 905 896 985
Operating Profit 153 151 102 117 118 96 91 110 124 138 147 142 135
OPM % 12% 13% 9% 11% 12% 10% 8% 11% 12% 13% 14% 14% 12%
7 7 9 8 9 9 10 10 10 9 8 11 11
Interest 5 7 6 11 13 15 14 14 15 12 14 13 12
Depreciation 31 30 30 32 34 34 36 39 40 40 39 41 41
Profit before tax 124 122 76 81 80 55 51 66 80 96 102 100 93
Tax % 32% 25% 31% 29% 28% 30% 43% 26% 26% 27% 27% 25% 25%
84 92 52 58 57 39 29 49 59 69 74 75 69
EPS in Rs 5.29 5.75 3.28 3.62 3.61 2.42 1.84 3.06 3.70 4.36 4.65 4.71 4.36
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 TTM
0 684 4,949 4,773 4,136 4,178 4,267
0 567 4,108 4,224 3,708 3,658 3,704
Operating Profit -0 117 841 549 427 519 562
OPM % 17% 17% 11% 10% 12% 13%
0 -10 22 32 29 38 40
Interest 0 7 31 22 53 56 51
Depreciation 0 22 123 122 136 158 161
Profit before tax -0 77 709 437 268 344 390
Tax % 0% 30% 33% 30% 32% 27%
-0 54 477 308 183 251 288
EPS in Rs -3.40 3.41 29.93 19.31 11.48 15.77 18.08
Dividend Payout % 0% 10% 17% 26% 43% 31%
Compounded Sales Growth
10 Years: %
5 Years: %
3 Years: -5%
TTM: 4%
Compounded Profit Growth
10 Years: %
5 Years: 331%
3 Years: -20%
TTM: 64%
Stock Price CAGR
10 Years: %
5 Years: %
3 Years: 9%
1 Year: -3%
Return on Equity
10 Years: %
5 Years: 12%
3 Years: 9%
Last Year: 9%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Equity Capital 0.05 16 16 16 16 16
Reserves -0 1,907 2,417 2,650 2,722 2,911
0 556 238 407 740 764
0 888 1,111 1,176 1,241 1,324
Total Liabilities 0 3,366 3,782 4,249 4,719 5,015
0 1,805 1,798 1,846 2,539 2,581
CWIP 0 65 174 525 331 525
Investments 0 50 6 8 15 37
0 1,446 1,804 1,870 1,834 1,872
Total Assets 0 3,366 3,782 4,249 4,719 5,015

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
0 112 453 462 430 508
0 33 -71 -469 -568 -389
0 -72 -418 42 144 -129
Net Cash Flow 0 73 -36 35 6 -9

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Debtor Days 251 43 39 50 53
Inventory Days 601 117 146 160 163
Days Payable 685 103 113 131 141
Cash Conversion Cycle 167 57 72 80 75
Working Capital Days 220 49 42 37 29
ROCE % 8% 29% 16% 10% 11%

Shareholding Pattern

Numbers in percentages

16 Recently
Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025
51.47% 51.47% 51.47% 51.47% 51.47% 51.47% 51.47% 51.47% 51.47% 51.47% 45.22% 45.22%
8.40% 7.73% 6.15% 6.30% 6.35% 6.58% 6.55% 7.22% 6.89% 7.12% 6.96% 5.96%
4.89% 5.97% 6.72% 9.18% 11.17% 13.60% 14.07% 15.47% 15.99% 15.91% 21.81% 23.04%
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.02%
35.03% 34.62% 34.83% 32.22% 30.17% 27.53% 27.10% 25.09% 24.90% 24.76% 25.30% 24.94%
0.19% 0.19% 0.82% 0.82% 0.82% 0.81% 0.81% 0.77% 0.74% 0.73% 0.72% 0.82%
No. of Shareholders 1,86,8951,85,0621,86,2941,73,5331,62,2021,50,3881,42,7361,25,3671,24,8301,20,4061,23,7481,25,749

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Credit ratings

Concalls